Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 9, keine Gesamtzahl für „Mono“
Suchtreffer
Begriffe & Kennungen
Brintellix · 4.3 · Concomitant use with nonselective monoamine oxidase inhibitors (MAOIs) or selective MAO-A inhibitors (see sect
Eintrag öffnenBrintellix · 4.3 · Concomitant use with nonselective monoamine oxidase inhibitors (MAOIs) or selective MAO-A inhibitors (see sect
Eintrag öffnenBromhexin
Eintrag öffnenBrown-Séquard-Syndrom
Eintrag öffnenBrukinsa · 4.8 · 9 Table 3: Adverse reactions of zanubrutinib monotherapy reported in clinical studies in patients with B-cell
Eintrag öffnenBrukinsa · 4.8 · Adverse reactions in patients treated with BRUKINSA as monotherapy or in combination with obinutuzumab for B-c
Eintrag öffnenBrukinsa · 4.8 · Adverse reactions in patients treated with BRUKINSA as monotherapy or in combination with obinutuzumab for B-c
Eintrag öffnenBrukinsa · 4.8 · Of the 1 550 patients treated with BRUKINSA monotherapy, 61.3% were 65 years of age or older. The incidence of
Eintrag öffnenBrukinsa · 4.8 · Of the 1 550 patients treated with BRUKINSA monotherapy, 61.3% were 65 years of age or older. The incidence of
Eintrag öffnenBrukinsa · 4.8 · Table 3: Adverse reactions of zanubrutinib monotherapy reported in clinical studies in patients with B-cell ma
Eintrag öffnenBrukinsa · 4.8 · The most common Grade 3 or higher adverse reactions (>3%) of zanubrutinib monotherapy were neutropenia§ (21%),
Eintrag öffnenBrukinsa · 4.8 · The most common Grade 3 or higher adverse reactions (>3%) of zanubrutinib monotherapy were neutropenia§ (21%),
Eintrag öffnenBrukinsa · 4.8 · The most commonly occurring adverse reactions (≥20%) of zanubrutinib monotherapy were upper respiratory tract
Eintrag öffnenBrukinsa · 4.8 · The most commonly occurring adverse reactions (≥20%) of zanubrutinib monotherapy were upper respiratory tract
Eintrag öffnenBrukinsa · 4.8 · The safety profile of zanubrutinib monotherapy is based on pooled data from 1 550 patients with B- cell malign
Eintrag öffnenBrukinsa · 4.8 · The safety profile of zanubrutinib monotherapy is based on pooled data from 1 550 patients with B- cell malign
Eintrag öffnenBrukinsa · 4.8 · Zanubrutinib monotherapy
Eintrag öffnenBrukinsa · 4.8 · Zanubrutinib monotherapy
Eintrag öffnenBucladesin
Eintrag öffnenBupivacain
Eintrag öffnen